Case Studies

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...

Challenge: A biotechnology company with clinical-stage assets positioned in several neuropsychiatric disorders wanted to supplement its internal pipeline with external innovation. The company wanted...

Challenge: Our client was developing a highly novel and versatile intracellular delivery vehicle which could readily penetrate cells without compromising membrane integrity or inducing cytotoxicity....

Challenge: Our client was developing a novel iron treatment with potential to be best-in-class for iron deficiency anemia (IDA). The product used nanotechnology to mimic the natural structure of...

Challenge: Our client was a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to inherited retinal diseases. The...

Challenge: A biotech company focused on developing therapeutics for fibrotic diseases was looking at acquisitions or in-licensing as a way to grow its development pipeline with additional assets....

Challenge: Our client was a publicly-traded precision oncology company with whom Alacrita had previously supported with a long-term asset scouting engagement. This cash-rich biotech company wanted to...

Challenge: A pharmaceutical company with a proprietary clinical trial technology made the strategic decision to diversify their development arm by acquiring and/or in-licensing pharmaceutical...